Streetbeat News

Price Targets

ARES

Barclays analyst Benjamin Budish maintains an Overweight rating on Ares Management (NYSE:ARES) and raises the price target from $126 to $130.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:11 pm

TSX:SCR

RBC Capital analyst Greg Pardy has initiated coverage on Strathcona Resources with a Sector Perform rating and a price target of C$35.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:11 pm

ACGL

Barclays analyst Tracy Benguigui maintains an Overweight rating on Arch Capital Group (NASDAQ:ACGL) and raises the price target from $92 to $96.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:10 pm

APO

Barclays analyst Benjamin Budish maintains an Overweight rating on Apollo Global Management (NYSE:APO) and raises the price target from $104 to $109.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:07 pm

PEP

Wedbush analyst Gerald Pascarelli has reiterated an Outperform rating on PepsiCo (NASDAQ:PEP) and maintained a $195 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:04 pm

LII

Goldman Sachs analyst Joe Ritchie maintains a Buy rating on Lennox Intl (NYSE:LII) and raises the price target from $332 to $455.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:03 pm

IMUX

Wedbush analyst Andreas Argyrides maintains an Outperform rating on Immunic (NASDAQ:IMUX) and raises the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:02 pm

KMB

Goldman Sachs analyst Jason English has maintained a Neutral rating on Kimberly-Clark (NYSE:KMB) and lowered the price target from $147 to $132.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 1:01 pm

ABCB

Ameris (NASDAQ:ABCB) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The company's average price target has increased by 8.98% from the previous average of $42.67 to $46.5. Analysts derive their ratings from various sources including company conference calls, financial statements, and insider conversations.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 1:00 pm

AQST

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on Aquestive Therapeutics (NASDAQ:AQST) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2023 | 12:59 pm